Recursion Pharmaceuticals Inc
$ 3.77
6.80%
25 Feb - close price
- Market Cap 1,965,161,000 USD
- Current Price $ 3.77
- High / Low $ 4.08 / 3.75
- Stock P/E N/A
- Book Value 2.17
- EPS -1.84
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.60 %
- 52 Week High 7.89
- 52 Week Low 2.98
About
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$6.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-05 | 2025-08-05 | 2025-05-07 | 2025-02-25 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-27 | 2023-11-09 | 2023-08-08 | 2023-05-08 |
| Reported EPS | -0.21 | -0.36 | -0.41 | -0.5 | -0.53 | -0.34 | -0.4 | -0.39 | -0.42 | -0.43 | -0.38 | -0.34 |
| Estimated EPS | -0.3 | -0.37 | -0.35 | -0.516 | -0.4168 | -0.35 | -0.4 | -0.42 | -0.45 | -0.38 | -0.37 | -0.35 |
| Surprise | 0.09 | 0.01 | -0.06 | 0.016 | -0.1132 | 0.01 | 0 | 0.03 | 0.03 | -0.05 | -0.01 | 0.01 |
| Surprise Percentage | 30% | 2.7027% | -17.1429% | 3.1008% | -27.1593% | 2.8571% | 0% | 7.1429% | 6.6667% | -13.1579% | -2.7027% | 2.8571% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.3067 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RXRX
2026-02-17 16:57:44
Recursion Pharmaceuticals is using inducement Restricted Stock Unit (RSU) awards to attract and retain talent in biotech and software, signaling ongoing hiring and investment in its workforce. This strategy aims to align new employees with shareholder outcomes but also raises concerns about potential share dilution. Investors are advised to monitor future disclosures regarding total share count and equity compensation expenses.
2026-02-10 19:58:30
Recursion Pharmaceuticals (RXRX) is highlighted in a new AI-driven bioengineering market study for its AI biology platform, despite recent weak share price performance. The stock is currently trading at $3.98, significantly below the analyst target of $7.00, suggesting it may be undervalued. However, its high P/S ratio compared to the industry indicates investors are already paying a premium.
2026-02-07 08:58:05
Borgeson Blake, a director at Recursion Pharmaceuticals (NASDAQ:RXRX), sold 220,000 shares for $924,000 on February 3, 2026, as per a Rule 10b5-1 trading plan. This sale occurred while RXRX shares had seen a 5% drop over the prior week and a 45% year-over-year decline. The company, despite holding more cash than debt, is not profitable and has a significant negative EBITDA.
2026-02-07 06:30:16
Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals (RXRX) for $924,000 on February 3, 2026, though the current stock price is below his selling price and the company faces profitability challenges despite holding more cash than debt. This sale occurred while the company reported promising Phase 1b/2 TUPELO trial results for REC-4881, leading JPMorgan to upgrade the stock to Overweight with an $11.00 price target. Recursion Pharmaceuticals plans to present updated clinical data from the TUPELO trial in a December 8, 2025 webinar to provide further insights into the drug's safety and efficacy for familial adenomatous polyposis (FAP).
2026-02-06 22:59:11
Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals (RXRX) for $924,000 on February 3, 2026, pursuant to a Rule 10b5-1 trading plan. This sale occurred as RXRX shares have declined, trading below Borgeson's selling price, despite recent promising TUPELO trial results for REC-4881 which led to a JPMorgan upgrade. The company, while cash-rich, is not profitable and has a negative EBITDA.
2026-01-26 21:28:02
Christopher Gibson, a director at Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 40,000 shares of Class A Common Stock for $178,800 and converted 40,000 Class B shares to Class A on January 20, 2026. Following these transactions, Gibson's direct and indirect holdings of Recursion Pharmaceuticals shares total over 1.7 million. This news comes as the company reported positive interim results for its investigational drug REC-4881 in treating familial adenomatous polyposis (FAP), leading to an "Overweight" upgrade from JPMorgan.
